EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteoglycan 4 (PRG4)/Lubricin and the Extracellular Matrix in Gout

Khaled A Elsaid iD, Gregory D Jay iD, Ru Liu-Bryan, Robert Terkeltaub iD

Gout, Urate, and Crystal Deposition Disease · 2023

DOI: 10.3390/gucdd1030012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gout, Urate, and Crystal Deposition Disease, 2023. Verfasst von Khaled A Elsaid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA 92618, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, NIAMS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteoglycan 4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblasts and superficial zone chondrocytes, released into synovial fluid, and adsorbed on cartilage and synovial surfaces. PRG4′s roles include cartilage boundary lubrication, synovial homeostasis, immunomodulation, and suppression of inflammation. Gouty arthritis is mediated by monosodium urate (MSU) crystal phagocytosis by synovial macrophages, with NLRP3 inflammasome activation and IL-1β release. The phagocytic receptor CD44 mediates MSU crystal uptake by macrophages. By binding CD44, PRG4 limits MSU crystal uptake and downstream inflammation. PRG4/CD44 signaling is transduced by protein phosphatase 2A, which inhibits NF-κB, decreases xanthine oxidoreductase (XOR), urate production, and ROS-mediated IL-1β secretion. PRG4 also suppresses MSU crystal deposition in vitro. In contrast to PRG4, collagen type II (CII) alters MSU crystal morphology and promotes the macrophage uptake of MSU crystals. PRG4 deficiency, mediated by imbalance in PRG4-degrading phagocyte proteases and their inhibitors, was recently implicated in erosive gout, independent of hyperuricemia. Thus, dysregulated extracellular matrix homeostasis, including deficient PRG4 and increased CII release, may promote incident gout and progression to erosive tophaceous joint disease. PRG4 supplementation may offer a new therapeutic option for gout.

Schlagwörter

Stichwörter der Autor:innen

PRG4collagen type IIgoutlubricinsynovium

Autor:innen und Institutionen

  • Department of Biomedical and Pharmaceutical Sciences, Chapman University, Irvine, CA 92618, USA.
  • Department of Emergency Medicine, Alpert Medical School of Brown University and School of Engineering, Brown University, Providence, RI 02903, USA.
  • VA San Diego Healthcare System, San Diego, CA 92161, USA.

ORCID-Profile: Khaled A Elsaid, Gregory D Jay, Robert Terkeltaub

Förderung

  • BLRD VA
  • NIAMS NIH HHS
  • NIA NIH HHS
  • NIH
  • Rheumatology Research Foundation Innovation Research Award
  • VA Research Service

Zitieren

APA

Elsaid, K. A., Jay, G. D., Liu-Bryan, R., & Terkeltaub, R. (2023). Proteoglycan 4 (PRG4)/Lubricin and the Extracellular Matrix in Gout. Gout, Urate, and Crystal Deposition Disease. https://doi.org/10.3390/gucdd1030012

Vancouver

Elsaid KA, Jay GD, Liu-Bryan R, Terkeltaub R. Proteoglycan 4 (PRG4)/Lubricin and the Extracellular Matrix in Gout. Gout, Urate, and Crystal Deposition Disease. 2023. doi:10.3390/gucdd1030012

BibTeX
@article{Elsaid2023,
  author = {Elsaid, Khaled A and Jay, Gregory D and Liu-Bryan, Ru and Terkeltaub, Robert},
  title = {Proteoglycan 4 (PRG4)/Lubricin and the Extracellular Matrix in Gout},
  journal = {Gout, Urate, and Crystal Deposition Disease},
  year = {2023},
  doi = {10.3390/gucdd1030012}
}
Kostenlos starten →